Generic Medicine Info
Hypersensitivity to kanamycin and other aminoglycosides.
Special Precautions
Patient w/ neuromuscular disorders (e.g. myasthenia gravis, parkinsonism, or infant botulism), pre-existing vertigo, tinnitus or hearing loss, hypocalcemia. Prolonged use may result in overgrowth of non-susceptible organisms. Renal impairment. Childn, premature infants, neonates. Pregnancy and lactation. Patient Counselling Maintain adequate fluid intake prior to and during therapy to minimise chemical irritation of renal tubules. Monitoring Parameters Monitor renal and auditory function.
Adverse Reactions
Ototoxicity, skin rash, drug fever, headache, paraesthesia, nausea, vomiting, diarrhoea, malabsorption syndrome characterised by an increase in faecal fat, decrease in serum carotene, and fall in xylose absorption; irritation or pain on inj site (IM).
Potentially Fatal: Nephrotoxicity, neuromuscular blockade w/ resp paralysis.
Drug Interactions
Additive nephrotoxic and neurotoxic effects w/ polymyxin B, bacitracin, colistin, amphotericin B, cisplatin, vancomycin, and other aminoglycosides (e.g. paromomycin). Enhanced toxicity w/ potent diuretics (e.g. ethacrynic acid, furosemide, meralluride Na, Na mercaptomerin, or mannitol). Increased risk of nephrotoxicity w/ cephalosporins. May potentiate the effects of succinylcholine and non-depolarising muscle relaxants (e.g. rocuronium). NSAIDs may increase concentrations of kanamycin.
CIMS Class
ATC Classification
S01AA24 - kanamycin ; Belongs to the class of antibiotics. Used in the treatment of eye infections.
A07AA08 - kanamycin ; Belongs to the class of antibiotics. Used in the treatment of intestinal infections.
J01GB04 - kanamycin ; Belongs to the class of other aminoglycosides. Used in the systemic treatment of infections.
Disclaimer: This information is independently developed by CIMS based on kanamycin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in